A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3).
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Clobetasol (Primary) ; Prednisone acetate
- Indications Ocular inflammation; Postoperative inflammation
- Focus Adverse reactions; Registrational
- Acronyms CLOSE-3
- Sponsors SALVAT
Most Recent Events
- 27 Sep 2024 Planned End Date changed from 31 Aug 2024 to 31 Dec 2025.
- 27 Sep 2024 Planned primary completion date changed from 31 Aug 2024 to 31 Dec 2025.
- 17 Oct 2022 New trial record